jg-231

JG-231 is a JG-98 analog with anticancer activity.JG-231 inhibits the MDA-MB-231 xenograft tumor model of triple-negative breast cancer (TNBC).JG-231 inhibits the interaction of Hsp70-BAG3.JG-231 inhibits the MDA-MB-231 xenograft tumor model of triple-negative breast cancer (TNBC). JG-231 inhibits MDA-MB-231 xenograft tumor model of triple negative breast cancer (TNBC).

PH11 is a novel Focal Adhesion Kinase (FAK) inhibitor. PH11 restores TRAIL apoptotic pathway in PANC-1 cells through down-regulation of c-FLIP via inhibition of FAK and the phosphatidylinositol-3 kinase (PI3K) AKT pathways. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) emerges as one of the most-promising experimental cancer therapeutic drugs and is currently being tested in clinical trials. However, both intrinsic and acquired resistance of human cancer cells to TRAIL-induced apoptosis poses a huge problem in establishing clinically efficient TRAIL therapies.

JG-98 is an allosteric Hsp70 inhibitor, displays high active against the breast cancer cell lines MDA-MB-231 and MCF-7 (EC50s: 0.4 0.7 μM).